Investors & Media

Inhibitor Therapeutics, Inc. (OTCQB:INTI) is a pharmaceutical development company that discovers, develops and plans to commercialize innovative therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders.  On August 20, 2019, we formally changed our corporate name from “HedgePath Pharmaceuticals, Inc.” to “Inhibitor Therapeutics, Inc.” and our stock symbol from “HPPI” to “INTI.”  On this page you will find important investor information.